Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis

Randomized, Open-label, Multi Centre Phase III Clinical Trial on Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis

Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite.

Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis.

Inclusion Criteria:

• Male and female patients older than 5 years and weighting > 15 kg
• Current residence in non-endemic areas
• Either direct diagnosis of S. stercoralis infection AND positive serology at any titer OR positive serology at "high" titer, irrespective of results of direct tests

Exclusion Criteria:

• Pregnant or lactating women
• Subjects suffering from CNS diseases
• Disseminated strongyloidiasis
• Immunocompromised patients.
• Lack of informed consent
• Previous treatment with ivermectin (in the last year)